Table 2.

Characteristics of scheduled VST treatment failures

Patient number	Indication for transplant	Conditioning intensity and graft	GVHD prophylaxis	EBV and CMV serostatus (donor/recipient)	Viral load prior to VST infusion	Transplant day at infusion	Criteria for treatment failure	Peak viral load by 100 d after transplant	Additional antiviral therapy (posttransplant day therapy started)	Status at last follow-up
1	ALL, CR1	MAC Haploidentical PBSC	T-cell depletion	CMV: −/+ EBV: +/+	Plasma BK 911	27	EBV viremia	536 198 (EBV)	Rituximab (day +94)	Dead, sepsis, day 675
9	FA	MAC MUD PBSC	T-cell depletion	CMV: +/− EBV: +/−	Plasma BK 927	21	Symptomatic BK viruria	11 837 (BKV)	None	Alive
20	SDS	RIC MUD Marrow	CSA, MMF, abatacept	CMV: −/indeterminate EBV: +/+	N/A	30	EBV viremia	528 917 (EBV)	Rituximab (day +82), 3rd party VST (day +83)	Alive
22	β-thalassemia	MAC MUD Marrow	Tacrolimus, MMF, abatacept	CMV: +/+ EBV: −/+	N/A	21	CMV viremia	9400 (CMV)	Valganciclovir (day+57)	Alive
26	NK lympho- proliferative disorder	RIC MUD Marrow	Tacrolimus, MMF	CMV: +/− EBV: +/+	N/A	21	Grade 3-4 GVHD	308 723 (ADV)	Cidofovir (day +98)	Dead, MOF, day 199

ALL, acute lymphoblastic leukemia; CSA, cyclosporine A; CR1, first complete remission; FA, Fanconi anemia; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MOF, multiorgan failure; MUD, matched unrelated donor; NK, natural killer cell; PBSC, peripheral blood stem cells; RIC, reduced intensity conditioning; SDS, Shwachman-Diamond syndrome; VST, virus-specific T cell.